Clinical trial of nicardipine cardioplegia in pediatric cardiac surgery.
To clarify the effectiveness of nicardipine, one of the dihydropyridine calcium-channel blockers, for myocardial protection during cold potassium cardioplegic arrest in pediatric cardiac surgery, a clinical trial of nicardipine (0.25 mg/L) added to potassium cardioplegic solution was performed in children undergoing surgical repair of congenital heart diseases. Twenty patients were selected to receive nicardipine cardioplegia and 13 patients received a standard potassium cardioplegia, serving as a control group. Nicardipine cardioplegia provided better cardiac performance in the early postoperative period and reduced release of the MB isozyme of creatine kinase, as determined during a 48-hour postoperative period. These results suggest that nicardipine added to cold potassium cardioplegic solution offers additional protection for the myocardium during ischemia and postischemic reperfusion in pediatric cardiac surgery.
Mori
F
F
First Department of Surgery, Yamaguchi University School of Medicine, Japan.
Miyamoto
M
M
Tsuboi
H
H
Noda
H
H
Esato
K
K
D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002314:Cardioplegic Solutions / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006321:Heart / Q000187:drug effects; D006324:Heart Arrest, Induced / Q000379:methods; D006330:Heart Defects, Congenital / Q000601:surgery*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007223:Infant; D007527:Isoenzymes; D008297:Male; D009529:Nicardipine / Q000627:therapeutic use*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D011897:Random Allocation
D002314:Cardioplegic Solutions; D007527:Isoenzymes; D009529:Nicardipine; D003402:Creatine Kinase